RT Journal Article
SR Electronic
T1 Early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of significantly decreased mortality
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.02.20206029
DO 10.1101/2020.10.02.20206029
A1 Eric Salazar
A1 Paul A. Christensen
A1 Edward A. Graviss
A1 Duc T. Nguyen
A1 Brian Castillo
A1 Jian Chen
A1 Bevin Valdez Lopez
A1 Todd N. Eagar
A1 Xin Yi
A1 Picheng Zhao
A1 John Rogers
A1 Ahmed Shehabeldin
A1 David Joseph
A1 Faisal Masud
A1 Christopher Leveque
A1 Randall J. Olsen
A1 David W. Bernard
A1 Jimmy Gollihar
A1 James M. Musser
YR 2020
UL http://medrxiv.org/content/early/2020/10/05/2020.10.02.20206029.abstract
AB Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 remains a global threat with few proven efficacious treatments. Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA). We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality. We here present results from 60-day follow up of our cohort of 351 transfused hospitalized patients. Prospective determination of ELISA anti-RBD IgG titer facilitated selection and transfusion of the highest titer units available. Retrospective analysis by the Ortho VITROS IgG assay revealed a median signal/cutoff (S/C) ratio of 24.0 for transfused units, a value far exceeding the recently FDA-required cutoff of 12.0 for designation of high titer convalescent plasma. With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma. In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.Competing Interest StatementES is the local principal investigator for a clinical trial sponsored by Regeneron assessing an investigational therapy for COVID-19.Funding StatementThis study was supported by the Fondren Foundation, Houston Methodist Hospital and Research Institute (to JMM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Houston Methodist Research Institute ethics review boardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available within the article or its supplementary materials.